Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Statement [Abstract]
Research and development	$ 15,842,959	$ 16,699,213
General, and administrative	11,750,080	12,802,735
Operating expenses	27,593,039	29,501,948
Operating loss	(27,593,039)	(29,501,948)
Other income (expense):
Other income (expense), net	273,101	23,854
Interest expense	(377,768)	(1,779,657)
Other income (expense) total	(104,667)	(1,755,803)
Loss before benefit from income taxes and noncontrolling interests	(27,697,706)	(31,257,751)
Benefit from income taxes	(11,526,557)	0
Net loss from continuing operations	(16,171,149)	(31,257,751)
Discontinued operations - net	38,399,236	(2,051,782)
Net income (loss)	22,228,087	(33,309,533)
Less - net loss from continuing operations attributable to noncontrolling interests	(182,457)	(241,802)
Less - net loss from discontinued operations attributable to noncontrolling interests	(568,156)	(411,412)
Net income (loss) attributable to Caladrius Biosciences, Inc. common shareholders	22,978,700	(32,656,319)
Amounts Attributable to Caladrius Inc. common shareholders:
Loss from continuing operations	(15,988,692)	(31,015,949)
Income (loss) from discontinued operations - net of taxes	38,967,392	(1,640,370)
Net income (loss) attributable to Caladrius Biosciences, Inc. common shareholders	$ 22,978,700	$ (32,656,319)
Basic earnings (loss)
Continuing operations (USD per share)	$ (1.78)	$ (4.74)
Discontinued operations (USD per share)	4.34	(0.25)
Caladrius Biosciences, Inc. common shareholders (USD per share)	2.56	(4.99)
Diluted earnings (loss)
Continuing operations (USD per share)	(1.78)	(4.74)
Discontinued operations (USD per share)	4.34	(0.25)
Caladrius Biosciences, Inc. common shareholders (USD per share)	$ 2.56	$ (4.99)
Weighted average common shares outstanding:
Basic shares	8,968,954	6,548,251
Diluted shares	8,968,954	6,548,251